Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 StudyThomas E. Witzig, Antonio Gualberto, Eric D. Jacobsen et al.|Blood|2019Cited by 10
Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 StudyThomas E. Witzig, Antonio Gualberto, Lubomir Sokol et al.|Blood|2018Cited by 2